International Journal of Cancer最新文献

{"title":"Life's Essential 8, genetic susceptibility, and risk of incident pancreatic cancer: A prospective cohort study.","authors":"Zhuo Wu, Liangtang Zeng, Zhou Fang, Yuan Yuan, Yu Zhou, Rufu Chen","doi":"10.1002/ijc.35184","DOIUrl":"https://doi.org/10.1002/ijc.35184","url":null,"abstract":"<p><p>The association between the American Heart Association (AHA) Life's Essential 8 (LE8) and the risk of pancreatic cancer (PC) remains unclear. Our goal was to assess the relationships between LE8, genetic susceptibility, and PC risk. This cohort consisted of 234,102 participants from the UK Biobank. The components of LE8 include diet, nicotine exposure, sleep, physical activity, blood glucose, body mass index, blood lipids, and blood pressure. LE8 is classified into three categories: low cardiovascular health (CVH), moderate CVH, and high CVH. Measurements were made using Cox proportional risk models to estimate impact of associations between LE8, genetic susceptibility, and incidence of PC in participants. Compared to participants with low LE8 scores, those with moderate and high LE8 scores had a 53% (HR, 0.47; 95% CI, 0.39-0.57) and 70% (HR, 0.30; 95% CI, 0.22-0.41) lower risk of developing PC, respectively. Interestingly, among individuals with high genetic risk, high LE8 scores were associated with greater benefits (HR, 0.24; 95% CI, 0.15-0.40), whereas the protective effect was weaker among those with low genetic risk (HR, 0.40; 95% CI, 0.21-0.75). Participants with a high LE8 score and a low polygenic risk score (PRS) had the lowest risk of PC (HR, 0.19; 95% CI: 0.11-0.33). Furthermore, we observed a significant additive interaction between LE8 and PRS. A higher LE8 score is associated with a lower risk of PC, especially for participants with a high PRS. These findings have important implications for participants most genetically predisposed to PC and for targeted strategies for PC prevention.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142277654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does use of anal cytology as a triage test improve the performance of high-risk human papillomavirus screening in gay and bisexual men for anal cancer prevention?","authors":"Fengyi Jin, I Mary Poynten, Richard J Hillman, Carmella Law, Monica Molano, Christopher K Fairley, Suzanne M Garland, David J Templeton, Andrew E Grulich, Jennifer Roberts","doi":"10.1002/ijc.35185","DOIUrl":"https://doi.org/10.1002/ijc.35185","url":null,"abstract":"<p><p>Anal high-risk human papillomavirus (HRHPV) testing-based anal cancer screening gay and bisexual men (GBM) is associated with high sensitivity, but low specificity. We report the potential role of triage use of anal cytology with HRHPV testing in detecting 12-month persistent anal high-grade squamous epithelial lesions (HSIL) in a cohort of GBM in Sydney, Australia. Participants were GBM from the Study of the Prevention of Anal Cancer (SPANC) who underwent annual anal HPV testing, cytology, and high-resolution anoscopy (HRA)-guided histology. The sensitivity and specificity of five screening algorithms based on HRHPV test results with triage use of anal cytology (atypical squamous cells of undetermined significance (ASCUS) and atypical squamous cells, cannot exclude HSIL (ASC-H) used as referral thresholds) were compared to these of HRHPV testing and anal cytology alone. A total of 475 men who had valid HRHPV, cytological, and histological results at both baseline and first annual follow-up visits were included, median age 49 years (inter-quartile range: 43-56) and 173 (36.4%) GBM with human immunodeficiency virus. Of all triage algorithms assessed, two had comparable sensitivity with HRHPV testing alone in detecting persistent anal HSIL, but ~20% higher specificity and 20% lower HRA referral rates. These two algorithms involved the immediate referral of those with HPV16 and for those with non-16 HRHPV either immediate or delayed (for 12 months) referral, depending on cytology result at baseline. Triage use of anal cytology in GBM testing positive for anal HRHPV increases specificity and reduces referral rates while maintaining high sensitivity in detection of HSIL.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142277653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Roles of leukemia inhibitory factor receptor in cancer","authors":"Wei Ma,&nbsp;Haixu Yan,&nbsp;Haoyuan Ma,&nbsp;Zengyan Xu,&nbsp;Wei Dai,&nbsp;Yudan Wu,&nbsp;Hongyan Zhang,&nbsp;Yanshu Li","doi":"10.1002/ijc.35157","DOIUrl":"10.1002/ijc.35157","url":null,"abstract":"<p>Leukemia inhibitory factor receptor (LIFR), in complex with glycoprotein 130 (gp130) as the receptor for leukemia inhibitory factor (LIF), can bind to a variety of cytokines and subsequently activate a variety of signaling pathways, including Janus kinase/signal transducer and activator of transcription 3. LIF, the most multifunctional cytokines of the interleukin-6 family acts as both a growth factor and a growth inhibitor in different types of tumors. LIF/LIFR signaling regulates a broad array of tumor-related processes including proliferation, apoptosis, migration, invasion. However, due to the activation of different signaling pathways, opposite regulatory effects are observed in certain tumor cells. Therefore, the role of LIFR in human cancers varies across different tumor and tissue, despite their recognized value in tumor treatment and prognosis observation is affirmed. Given its aberrant expression in numerous tumor cells and crucial regulatory function in tumorigenesis and progression, LIFR is considered as a promising targeted therapeutic agent. This review provides an overview of LIFR's initiating signaling pathway function as a cytokine receptor and summarize the current literature on the role of LIFR in cancer and its possible use in therapy.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"156 2","pages":"262-273"},"PeriodicalIF":5.7,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142277660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A narrative review on advances in neoadjuvant immunotherapy for esophageal cancer: Molecular biomarkers and future directions","authors":"Wenjing Wang,&nbsp;Lisha Ye,&nbsp;Huihui Li,&nbsp;Wei Chen,&nbsp;Wei Hong,&nbsp;Weimin Mao,&nbsp;Xiaoling Xu","doi":"10.1002/ijc.35153","DOIUrl":"10.1002/ijc.35153","url":null,"abstract":"<p>Esophageal cancer has a poor prognosis and survival rate due to its high incidence in Asia, lack of early symptoms and limited treatment options. In recent years, many clinical trials have demonstrated that immunotherapy has greatly improved the survival of patients with esophageal cancer. In addition, the combination of neoadjuvant immunotherapy with other popular therapeutic regimens has shown good efficacy and safety. In this review, we summarize the progress of clinical trials and some breakthroughs in neoadjuvant immunotherapy for esophageal cancer in recent years and suggest the possibility of multimodal neoadjuvant immunotherapy regimens, as well as directions for future development.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"156 1","pages":"20-33"},"PeriodicalIF":5.7,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142248980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"World Cancer Congress IJC abstract supplementPreface","authors":"","doi":"10.1002/ijc.35158","DOIUrl":"https://doi.org/10.1002/ijc.35158","url":null,"abstract":"<p>It is with great pleasure that we present this collection of abstracts, selected from the top 200 submissions to the 2024 World Cancer Congress, held in Geneva, Switzerland, from the 17^th to the 19^th of September. This compilation reflects the diversity, innovation, and pursuit of knowledge from researchers, programme managers, policy makers and advocates from around the world. It characterises the tremendous range of efforts that are being deployed to address the rising numbers of cancer cases and related deaths globally.</p><p>The abstracts in this supplement are organised around the six programme themes of the World Cancer Congress: Prevention, Screening and Early Detection; Cancer Research and Progress; Health Care Systems and Policies; Cancer Treatment and Palliative Care; Tobacco Control; and People Living with Cancer. Each theme represents a critical component of cancer control efforts and provides a window into cancer research and practice, as well as the policy and programme initiatives that are shaping the future of cancer prevention, detection, treatment, and care.</p><p>The abstracts include scientific studies that deepen our understanding of recent scientific and clinical advances in aetiology, prevention, diagnosis, and treatment of cancer, practice and policy reports that highlight successful interventions and systems improvements, and summaries of fundraising efforts that sustain critical programmes and services. The abstracts related to ‘People living with Cancer’ give voice to those with lived experience of cancer, presenting research and reports that focus on improving quality of life and providing holistic support.</p><p>We extend our deepest gratitude to all the contributors, reviewers, executive programme leads, theme co-chairs, and sponsors who have made this conference possible. It is through your unwavering commitment that we continue to make strides toward a world where cancer is no longer a formidable threat to human health and well-being and where all people, no matter who they are or where they live, have access to the services and programmes they need.</p><p>Abstract Committee</p><p>David Hill, David Collingridge and Sonali Johnson</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"155 S1","pages":"3"},"PeriodicalIF":5.7,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ijc.35158","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142231028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of novel candidate predisposing genes in familial nonmedullary thyroid carcinoma implicating DNA damage repair pathways","authors":"Carolina Pires,&nbsp;Inês J. Marques,&nbsp;Ana Saramago,&nbsp;Margarida M. Moura,&nbsp;Marta Pojo,&nbsp;Rafael Cabrera,&nbsp;Catarina Santos,&nbsp;Francisco Rosário,&nbsp;Diana Lousa,&nbsp;João B. Vicente,&nbsp;Tiago M. Bandeiras,&nbsp;Manuel R. Teixeira,&nbsp;Valeriano Leite,&nbsp;Branca M. Cavaco","doi":"10.1002/ijc.35159","DOIUrl":"10.1002/ijc.35159","url":null,"abstract":"<p>The genetic basis of nonsyndromic familial nonmedullary thyroid carcinoma (FNMTC) is still poorly understood, as the susceptibility genes identified so far only account for a small percentage of the genetic burden. Recently, germline mutations in DNA repair-related genes have been reported in cases with thyroid cancer. In order to clarify the genetic basis of FNMTC, 94 genes involved in hereditary cancer predisposition, including DNA repair genes, were analyzed in 48 probands from FNMTC families, through targeted next-generation sequencing (NGS). Genetic variants were selected upon bioinformatics analysis and in silico studies. Structural modeling and network analysis were also performed. In silico results of NGS data unveiled likely pathogenic germline variants in 15 families with FNMTC, in genes encoding proteins involved in DNA repair (<i>ATM</i>, <i>CHEK2</i>, <i>ERCC2</i>, <i>BRCA2</i>, <i>ERCC4</i>, <i>FANCA</i>, <i>FANCD2</i>, <i>FANCF</i>, and <i>PALB2</i>) and in the <i>DICER1</i>, <i>FLCN</i>, <i>PTCH1</i>, <i>BUB1B</i>, and <i>RHBDF2</i> genes. Structural modeling predicted that most missense variants resulted in the disruption of networks of interactions between residues, with implications for local secondary and tertiary structure elements. Functional annotation and network analyses showed that the involved DNA repair proteins functionally interact with each other, within the same DNA repair pathway and across different pathways. MAPK activation was a common event in tumor progression. This study supports that rare germline variants in DNA repair genes may be accountable for FNMTC susceptibility, with potential future utility in patients' clinical management, and reinforces the relevance of <i>DICER1</i> in disease etiology.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"156 1","pages":"130-144"},"PeriodicalIF":5.7,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ijc.35159","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142188176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and evaluation of a serum microRNA panel to diagnose colorectal cancer patients.","authors":"Lui Ng, Ryan Wai-Yan Sin, David Him Cheung, Carlos King-Ho Wong, Cindy Lo-Kuen Lam, Wai-Keung Leung, Wai-Lun Law, Dominic Chi-Chung Foo","doi":"10.1002/ijc.35175","DOIUrl":"https://doi.org/10.1002/ijc.35175","url":null,"abstract":"<p><p>Screening plays a crucial role in the early detection of colorectal cancer, greatly reducing mortality rates. The objective of this study was to identify a non-invasive diagnostic method utilizing serum microRNA expression for the diagnosis of colorectal cancer patients. The study consisted of three stages. In the first stage, 129 patients with colorectal cancer and 129 normal subjects were recruited as the training set for the development of a blood miRNA panel. The second stage involved recruiting 200 patients from each group as the validation cohort. Finally, a blinded study was conducted in the third stage, with 260 patients recruited to determine the predictive value of our miRNA panel. Serum samples were prospectively collected from colorectal cancer patients and normal subjects between 2017 and 2021 at Queen Mary Hospital in Hong Kong. Quantitative PCR was utilized to detect the serum levels of candidate microRNAs, and a multiple linear regression model was employed to formulate a serum microRNA panel for diagnosing colorectal cancer patients. The performance of the panel was evaluated using ROC analysis. Our study showed that the values of three pairs of serum microRNAs, namely miR-106b-5p/miR-1246, miR-106b-5p/miR-16 and miR-106b-5p/miR-21-5p, exhibited statistically significant differences between colorectal cancer patients and normal subjects. A serum microRNA panel formulated from these three pairs of microRNAs demonstrated high accuracy in diagnosing colorectal cancer patients from normal subjects, with an AUC of approximately 0.9. The serum miRNA test proved to be a feasible and promising non-invasive biomarker for the diagnosis of colorectal cancer patients in comparison to normal subjects.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142152723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uncovering possible silent acquired long QT syndrome using exercise stress testing in long-term pediatric acute lymphoblastic leukemia survivors","authors":"Audrey Harvey,&nbsp;Maxime Caru,&nbsp;Cecilia Gonzalez Corcia,&nbsp;Émilie Bertrand,&nbsp;Vincent Gagné,&nbsp;Smita Dandekar,&nbsp;Maja Krajinovic,&nbsp;Hugo Gravel,&nbsp;Caroline Laverdière,&nbsp;Marie-Josée Raboisson,&nbsp;Gregor Andelfinger,&nbsp;Vincent Jacquemet,&nbsp;Daniel Sinnett,&nbsp;Daniel Curnier","doi":"10.1002/ijc.35168","DOIUrl":"10.1002/ijc.35168","url":null,"abstract":"<p>An example of chemotherapy-induced cardiotoxicity in cancer survivors is acquired long QT syndrome (aLQTS), which may cause serious yet preventable life-threatening consequences. Our objective was to identify and characterize childhood acute lymphoblastic leukemia (ALL) survivors with possible aLQTS using maximal exercise testing. In this cross-sectional study with exploratory analysis, a total of 250 childhood ALL survivors were evaluated for abnormal QT interval prolongation using the McMaster cycle exercise test. A total of 198 survivors (102 males; 96 females), having reached their <span></span><math>\u0000 <mrow>\u0000 <mover>\u0000 <mi>V</mi>\u0000 <mo>̇</mo>\u0000 </mover>\u0000 <msub>\u0000 <mi>O</mi>\u0000 <mn>2</mn>\u0000 </msub>\u0000 </mrow></math> peak (mean 32.1 ± 8.4 mL/kg/min; range 15.5–57.8 mL/kg/min), were included in our analyses. Two survivors were excluded for possible congenital LQTS. QT intervals were corrected for heart rate using the Bazett, Fridericia, and Rautaharju formulas at rest (supine, sitting, and standing positions), at the end of each stage of the CPET, and at 1, 3, and 5 minutes into the recovery period. The corrected QT (QTc) of borderline (<i>n</i> = 37) and long QT survivors (<i>n</i> = 20) was significantly longer than normal survivors (<i>n</i> = 141) at rest, exercise, and recovery. Out of 57 survivors presenting an abnormal QTc prolongation, 40 survivors (70%) showed no QT interval anomalies at rest but developed various anomalies during exercise. No significant differences were found between the groups for any of the measured clinical characteristics or cardiac parameters. The standardization of exercise testing in the regular follow-up of oncology patients is necessary for appropriate cardiac prevention and surveillance to enhance the health and quality of life of the ever-increasing number of cancer survivors.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"156 2","pages":"403-416"},"PeriodicalIF":5.7,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ijc.35168","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142152724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FHL2 expression by cancer-associated fibroblasts promotes metastasis and angiogenesis in lung adenocarcinoma","authors":"Ryu Kanzaki,&nbsp;Steven Reid,&nbsp;Paulina Bolivar,&nbsp;Jonas Sjölund,&nbsp;Johan Staaf,&nbsp;Sara Larsson,&nbsp;Yasushi Shintani,&nbsp;Kristian Pietras","doi":"10.1002/ijc.35174","DOIUrl":"10.1002/ijc.35174","url":null,"abstract":"<p>Cancer-associated fibroblasts (CAFs) contribute to the progression of lung cancer. Four and a half LIM domain protein-2 (FHL2) is a component of focal adhesion structures. We analyzed the function of FHL2 expressed by CAFs in lung adenocarcinoma. Expression of FHL2 in fibroblast subtypes was investigated using database of single-cell RNA-sequencing of lung cancer tissue. The role of FHL2 in the proliferation and migration of CAFs was assessed. The effects of FHL2 knockout on the migration and invasion of human lung adenocarcinoma cells and tube formation of endothelial cells induced by CAF-conditioned medium (CM) were evaluated. The effect of FHL2 knockout in CAFs on metastasis was determined using a murine orthotopic lung cancer model. The prognostic significance of stromal FHL2 was assessed by immunohistochemistry in human adenocarcinoma specimens. FHL2 is highly expressed in myofibroblasts in cancer tissue. TGF-β1 upregulated FHL2 expression in CAFs and FHL2 knockdown attenuated CAF proliferation. FHL2 knockout reduced CAF induced migration of A110L and H23 human lung adenocarcinoma cell lines, and the induction of tube formation of endothelial cells. FHL2 knockout reduced CAF-induced metastasis of lung adenocarcinomas in an orthotopic model in vivo. The concentration of Osteopontin (OPN) in CM from CAF was downregulated by FHL2 knockout. siRNA silencing and antibody blocking of OPN reduced the pro-migratory effect of CM from CAF on lung cancer cells. In resected lung adenocarcinoma specimens, positive stromal FHL2 expression was significantly associated with higher microvascular density and worse prognosis. In conclusion, FHL2 expression by CAFs enhances the progression of lung adenocarcinoma by promoting angiogenesis and metastasis.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"156 2","pages":"431-446"},"PeriodicalIF":5.7,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ijc.35174","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142152722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)","authors":"Chiara Ciccarese,&nbsp;Thomas Büttner,&nbsp;Linda Cerbone,&nbsp;Ilaria Zampiva,&nbsp;Fernando Sabino M. Monteiro,&nbsp;Umberto Basso,&nbsp;Martin Pichler,&nbsp;Maria Giuseppa Vitale,&nbsp;Ondrej Fiala,&nbsp;Giandomenico Roviello,&nbsp;Ray Manneh Kopp,&nbsp;Francesco Carrozza,&nbsp;Renate Pichler,&nbsp;Francesco Grillone,&nbsp;Esther Pérez Calabuig,&nbsp;Annalisa Zeppellini,&nbsp;Zsófia Küronya,&nbsp;Luca Galli,&nbsp;Gaetano Facchini,&nbsp;Kaisa Sunela,&nbsp;Alessandra Mosca,&nbsp;Javier Molina-Cerrillo,&nbsp;Gian Paolo Spinelli,&nbsp;Jawaher Ansari,&nbsp;Alessandro Scala,&nbsp;Veronica Mollica,&nbsp;Enrique Grande,&nbsp;Sebastiano Buti,&nbsp;Ravindran Kanesvaran,&nbsp;Roubini Zakopoulou,&nbsp;Aristotelis Bamias,&nbsp;Mimma Rizzo,&nbsp;Francesco Massari,&nbsp;Roberto Iacovelli,&nbsp;Matteo Santoni","doi":"10.1002/ijc.35141","DOIUrl":"10.1002/ijc.35141","url":null,"abstract":"<p>Metastatic renal cell carcinoma (mRCC) carrying sarcomatoid features (sRCC) has aggressive biology and poor prognosis. First-line immunotherapy (IO)-based combinations have improved the outcome of clear cell RCC patients, including that of sRCC. Real-world data confirming the adequate first-line management of sRCC is largely lacking. We investigated the clinical features and the outcome of sRCC patients treated with IO-based combinations within the ARON-1 study population (NCT05287464). The primary objective was to define the incidence and baseline clinical characteristics of sRCC compared with non-sRCC patients. The secondary objective was to describe the outcome of sRCC patients based on type of first-line treatment (IO + IO vs. IO + tyrosin kinase inhibitor [TKI]). We identified 1362 mRCC patients with IMDC intermediate or poor risk, 226 sRCC and 1136 non-sRCC. These two subgroups did not differ in terms of baseline characteristics. The median overall survival (OS) was 26.8 months (95%CI 21.6–44.2) in sRCC and 35.3 months (95%CI 30.2–40.4) in non-sRCC patients (<i>p</i> = .013). The median progression-free survival (PFS) was longer in non-sRCC patients compared to sRCC (14.5 vs. 12.3 months, <i>p</i> = .064). In patients treated with first-line IO + TKI the median OS was 34.4 months compared to 26.4 months of those who received IO + IO (<i>p</i> = .729). The median PFS was 12.4 months with IO + TKI and 12.3 months with IO + IO (<i>p</i> = .606). In conclusion, we confirm that sRCC are aggressive tumors with poor prognosis. IO-based combinations improve survival outcomes of sRCC patients, regardless from the type of strategy (IO + IO versus IO + TKI) adopted.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"155 11","pages":"2036-2046"},"PeriodicalIF":5.7,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ijc.35141","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142144510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}